AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: [14C] AZD5069
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01332903
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
Phase 1
Completed
- Conditions
- Healthy VolunteersBioequivalence
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2011-10-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT01331993
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA
- Conditions
- NSCLC Patient Characteristics
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT01330862
- Locations
- 🇸🇦
Research Site, Jeddah, Western, Saudi Arabia
A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT01330758
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1945
- Registration Number
- NCT01329029
- Locations
- 🇦🇺
Nycomed Investigational site, Daws Park, Australia
🇬🇧Nycomed Investigational Site, Norwich, United Kingdom
Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients
Completed
- Conditions
- Asthma
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2815
- Registration Number
- NCT01327001
- Locations
- 🇨🇿
Research Site, Znojmo, Czech Republic
Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 497
- Registration Number
- NCT01325948
- Locations
- 🇹🇷
Research Site, Yozgat, Turkey
An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease
Phase 1
Completed
- Conditions
- Maximum Diagnostic Mass of [18Fluor]AZD4694
- Interventions
- Other: [18Fluor]AZD4694
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT01325402
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Amount of NKTR-118 in BloodVariation in the Heart's Electrical Cycle
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT01325415
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT01323790
- Locations
- 🇬🇧
Research Site, Derby, United Kingdom